Evaluation of clopidogrel in inhibition of platelet aggregation

Evaluation of in-vivo therapeutic effects of Clopidogrel 75mg [Lowplat] given once daily for seven days to the patients requiring antiplatetet therapy. This is an open label, multicenter study to determine the platelet aggregation inhibition of the study drug in adult subjects suffering from diseases requiring antiplatelet therapy i.e. coronary artery diseases [CAD], peripheral vascular diseases [PVD] and cerebro vascular accident [CVA], presented at different hospitals and clinics in Faisalabad. Mean platelet aggregation inhibited by [LP] was 66% [P <0.001] and standard deviation was +/- 10%, which is statistically significant. This study proves that the Lowplat [LP] is effective in reducing platelet aggregation significantly in Pakistani patients' who require antiplatelet therapy. The cost benefit of locally manufactured drug may be passed on to the patients

What is partial glucocorticoid resistance syndrome? hypertension in young adults

As we all know in most of the patients with hypertension etiology is unknown. Essential hypertension is often very difficult to treat adequately in young patients. Multiple endocrine disorders have been found to be involved in the pathogenesis of hypertension. Glucocorticoids have got some complex mechanism in the metabolism, and controlling the blood pressure. There is some definite association of cortisol with the regulation of blood pressure by having some effect through glucocorticoid receptors. Recently in adult patients who presented with hypertension at relatively younger age at or before 35 years of age a new etiological pathology have been found, known as partial glucocorticoid resistance syndrome. This is a review article